Clinical Trial Update: HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating valproic acid, an HDAC inhibitor, for chronic lymphocytic leukemia was terminated. The study status indicates the trial was ended befor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• VALPROIC ACID (Valproic acid)

Snippet

Sponsor: CancerCare Manitoba | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED